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Abstract
Background: It is well known that the standard doses of a given drug may not have equivalent effects in all
patients. To date, the management of depression remains mainly empirical and often poorly evaluated. The
development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance,
and hence the burden and costs of mood depressive disorders.
The Geneva Cocktail Phenotypic approach presents several advantages including the “in vivo” measure of different
cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the
influence of variability over time on phenotyping results, the administration of low dose substrates, a limited
sampling strategy with an analytical method developed on DBS analysis.
The goal of this project is to explore the relationship between the activity of drug-metabolizing enzymes (DME),
assessed by a phenotypic approach, and the concentrations of Venlafaxine (VLX) + O-demethyl-venlafaxine (ODV),
the efficacy and tolerance of VLX.
Methods/design: This study is a multicentre prospective non-randomized open trial. Eligible patients present a
major depressive episode, MADRS over or equal to 20, treatment with VLX regardless of the dose during at least
4 weeks. The Phenotype Visit includes VLX and ODV concentration measurement.
Following the oral absorption of low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine, drug
metabolizing enzymes activity is assessed by specific metabolite/probe concentration ratios from a sample taken
2 h after cocktail administration for CYP2C19, CYP3A4, CYP2D6; and by the determination of the limited area under
the curve from the capillary blood samples taken 2–3 and 6 h after cocktail administration for CYP2C19 and P-gp.
(Continued on next page)
* Correspondence: celialloret@yahoo.fr; celia.lloret-linares@aphp.fr
1Inserm, U1144, F-75006 Paris, France
2Université Paris Diderot, UMR-S 1144, F-75013 Paris, France
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lloret-Linares et al. BMC Pharmacology and Toxicology  (2017) 18:70 
DOI 10.1186/s40360-017-0173-2
(Continued from previous page)
Two follow-up visits will take place between 25 and 40 days and 50–70 days after inclusion. They include assessment
of efficacy, tolerance and observance.
Eleven french centres are involved in recruitment, expected to be completed within approximately 2 years with 205
patients. Metabolic ratios are determined in Geneva, Switzerland.
Discussion: By showing an association between drug metabolism and VLX concentrations, efficacy and tolerance,
there is a hope that testing drug metabolism pathways with a phenotypical approach would help physicians in
selecting and dosing antidepressants. The MARVEL study will provide an important contribution to increasing the
knowledge of VLX variability and in optimizing the use of methods of personalized therapy in psychiatric settings.
Trial registration: ClinicalTrials.gov NCT02590185 (10/27/2015). This study is currently recruiting participants.
Background
Challenge in depression management
A recent epidemiological study has shown major depres-
sive disorder (MDD) to be associated with a significant
morbidity burden; it has the second largest proportion
of individuals living with disability worldwide and in this
respect is second only to low back pain [1]. Mood disor-
ders are the most prominent and the most expensive
brain disorders in Europe [2]; the total annual cost per
disorder was €113.4 billion in 2010, slightly higher than
dementia, but tenfold the cost of epilepsy or Parkinson’s
disease and two-fold the cost of stroke [3]. Direct cost
constituting the majority of the total cost with the re-
mainder being attributable to indirect costs associated
with patients’ production losses.
All costs are increased due to unpredictable response to
antidepressant therapy [4]; despite the availability of an in-
creasing number of pharmacological treatments for MDD,
only 25 to 35% of the patients recover fully from a depres-
sive episode after first line treatment, necessitating either a
trial of a second antidepressant or an augmentation strat-
egy. In addition, many patients do not recover to a durable,
long-term functional remission [5, 6]. Patients with resist-
ance to treatment are twice as likely to be hospitalized, have
more outpatient visits, use more psychotropic medications,
and have 19 times the depression-related costs compared
to patients with depression that responds to treatment [7].
It is well known that the standard doses of a given drug
may not have equivalent effects in all patients. To date,
the management of depression remains mainly empirical
and often poorly evaluated. Thus the costs associated with
MDD might be mitigated by the individualization of its
treatment; the development of a personalized medicine in
psychiatry may reduce treatment failure, intolerance or re-
sistance, and hence the burden and costs of MDD.
Emergence of pharmacokinetic biomarkers of
antidepressant efficacy
Progress towards individualization requires an under-
standing of the origins of response variability and the
development of strategies to manage it. Factors that
cause variability in antidepressant response are complex;
they include modifiable and non-modifiable, pharmaco-
kinetic (PK) and pharmacodynamic (PD) factors [8]. PK
factors are emerging as attractive predictive markers of
drug response, particularly as no suitable markers re-
lated to antidepressant mechanisms of action have so far
been identified. Studies of different classes of antidepres-
sants in both clinical trials and clinical settings have
shown a relationship between drug concentrations, the
magnitude and the duration of pharmacologic effects;
thus an understanding of an individual PK profile may
allow antidepressant response variability to be accounted
for in the choice of therapeutic agent.
The GeneSight pharmacogenomic test and interpretive
report has been designed to predict antidepressant re-
sponses based on DNA variations in cytochrome P450
genes (CYP2D6, CYP2C19, CYP2C9 and CYP1A2), the
serotonin transporter gene (SLC6A4) and the serotonin
2A receptor gene (5HTR2A) [9]. This algorithm is based
on the genotyping of both copies of five pharmacoki-
netic and pharmacodynamic genes selected for their
relevance to clinical response to antidepressants and
antipsychotics.
Three prospective clinical studies confirmed the benefit
of such investigations for the management treatment-
resistant depression. The odds of clinical response were
increased 2.3-fold among all GeneSight-guided treatments
compared to all treated as usual subjects (p = 0.004), the
guided group had a 53% greater improvement in depres-
sive symptoms (p = 0.0002), a 1.7-fold relative improve-
ment in response (p = 0.01), and a number needed to
treat for one clinical response above that seen in the
treated as usual group of 6.07 [10].
In a retrospective study, Winner et al. evaluated eight
direct or indirect health care utilization measures for 96
patients with a diagnosis of depressive or anxiety disorder
[11]. The eight measures were evaluated in relation to the
pharmacogenomics test and reporting system. Subjects
whose medication regimen included a medication identi-
fied by the test as most problematic (medication status of
‘use with caution and frequent monitoring’), had 69%
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more total health care visits, 67% more general medical
visits, greater than three-fold more medical absence days,
and greater than four-fold more disability claims than
subjects taking drugs categorized as ‘use as directed’ or
‘use with caution’. The test can identify past inappropriate
medication selection, which led to increased healthcare
utilization and cost. Moreover, pharmacogenomics test in
patients who had switched or added a new psychiatric
medication after having failed monotherapy provides sig-
nificant ‘real world’ cost savings, while simultaneously im-
proving adherence [12].
Clinical investigation of drug metabolism
Drug metabolism may be affected to varying degrees by
physiological and pathological factors and by drug-drug
interactions involving metabolizing enzymes as well as
by genetic polymorphism.
Genotyping
The activity of the enzymes and transporters involved in
drug PK parameters may be influenced by their genetic
variation. For a subset of alleles in vivo and in vitro studies
have elucidated enzyme activities that are listed as in-
creased, normal, decreased, absent or unknown. This list
is available in ‘The Human Cytochrome P450 (CYP) Allele
Nomenclature Database’ (http://www.PharmVar.org),
which catalogues genetic variability in CYP enzymes. This
information can be used, along with the number of func-
tional alleles and the presence of gene duplications, to pre-
dict the metabolic phenotypes.
Poor or slow metabolizers (PMs) have deficient metab-
olizing ability compared with persons with normal activity.
PMs relative to more rapid metabolizers are more likely to
suffer from adverse drug effects when taking normal doses
of drugs that are active per se and are metabolized mainly
via these pathways. Conversely, an increased amount of
active metabolites in ultrarapid metabolizers (UMs) may
induce side effects resulting in reduced tolerability.
Furthermore in UMs increased metabolism of active drug
to inactive metabolite is likely to result in a reduced effi-
cacy relative to the slower metabolic phenotypes. Between
these two extreme profiles, intermediate (IMs) and exten-
sive (EMs) profiles have also been described. The distribu-
tion of phenotypes differs according to ethnic origin [13].
Moreover, the number of phenotypes depends on the
CYP; for certain CYP’s and for the P-glycoprotein (P-gp),
three phenotypes of activity are described (reduced, nor-
mal, induced).
Phenotyping
Approaches based on gene polymorphism identification
may not provide an accurate estimate because of poor
genotype/phenotype correlation for some genes in cer-
tain clinical situations [13–19]. The phenotypic approach
can effectively assess Drug Metabolizing Enzyme
(DME) activity independently of a specific treatment,
even before starting it [9, 20, 21]. Phenotyping consists
of the administration of probe substrates metabolised
by a specific CYP or transported by P-gp, followed by
the determination of a metabolic ratio (MR) or the
evaluation of the plasma or urine probes’ concentra-
tions. The major strength of this approach is the direct
measure of CYP activity, including genetic, physio-
logical and environmental factors. Classification by
phenotype is based on drug concentration or blood or
urinary metabolic ratio [22, 23]. Phenotyping tests can
be either individual or simultaneous; individual pheno-
typing involves administration of one CYP specific
probe, while simultaneous phenotyping involves con-
comitant administration of multiple specific probes
(probe cocktail) and allows the detection of the activity
of multiple enzymes simultaneously.
Venlafaxine
Venlafaxine (VLX) is a serotonin–norepinephrine re-
uptake inhibitor marketed for the treatment of depression
disorders. It provides a reasonable second-step choice for
patients with depression and is used extensively in psychi-
atric practice [24, 25]. Regarding differences in efficacy
and tolerability between “newer” antidepressants, Cipriani
et al. found in a meta-analysis of 117 randomized clinical
trials with 25,928 patients that mirtazapine, escitalopram,
VLX, and sertraline were significantly more efficacious
than duloxetine, fluoxetine, fluvoxamine, paroxetine, and
reboxetine [25].
Pharmacology
VLX is primarily metabolised into the active metabolite
O-desmethyl-VLX (ODV), with serotonin and nor-
adrenaline reuptake inhibition properties. The mean
plasma half-lives (± SD) of VLX and ODV are 5(±2)
hours and 11(±2) hours, respectively. Steady-state con-
centrations of VLX and ODV are attained within 3 days
of oral multiple-dose therapy. VLX and ODV exhibit
linear kinetics over the dose range of 75 mg to 450 mg/
day [26]. Absolute bioavailability is 40% to 45% due to
pre-systemic metabolism. VLX and ODV are minimally
bound at therapeutic concentrations to human plasma
proteins (25–30%, approximately). The volume of distri-
bution for VLX at steady-state is 4.4 ± 1.6 L/kg following
intravenous administration.
The therapeutic range of VEN + ODV in blood is between
125 and 400 μg/l [27].
VLX is highly metabolized in humans, with urinary
excretion of the unchanged compound being between 1
and 10% of an administered dose [28]. Cytochrome P450
2D6 (CYP2D6) is the major enzyme involved in ODV
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formation, which is excreted unchanged and as its glucu-
ronide. Despite the major role of CYP2D6, ODV concen-
trations are detectable in CYP2D6 PMs and CYP2C19
may also be involved in the formation of ODV to a minor
extent [29, 30]. N-Demethylation of VLX to the inactive
metabolite N-desmethyl-VLX (NDV) by CYP3A4 and
CYP2C19 is generally a minor metabolic pathway [29, 31].
Patients with the CYP2D6 PM phenotype show a higher
level of NDV compared with CYP2D6 EM patients, impli-
cating an increase in flux through this route when ODV
production is reduced [32, 33].
ODV and NDV are further metabolized by CYP2C19,
CYP2D6, and/or CYP3A4 into N,O-didesmethyl-VLX, a
minor metabolite with no known pharmacological effect,
which is itself metabolized into N,N,O-tridesmethyl-
VLX or excreted as its glucuronide (Fig. 1.).
CYP variability and VLX
The effect of CYP2C19 in VLX metabolism and efficacy
has not been extensively studied to date. As both PM and
UM variations of CYP2C19 are present in most popula-
tions, it is reasonable to expect that CYP2C19 variability
may have an impact on VLX metabolism, particularly in
patients carrying CYP2D6 PM and IM phenotypes. In
addition, as VLX is a weak inhibitor of CYP2D6 and
CYP3A4, CYP2C19 pathways are though to be signifi-
cantly involved in ODV metabolism [34].
Some studies have indicated that polymorphisms in
both CYP2D6 and CYP2C19 influenced VLX metabolism
[8]. Moreover the combined missing CYP2D6 and
CYP2C19 activity has been involved in the occurrence of
a fatal drug poisoning case in a patient receiving VLX
[35]. McAlpine et al. showed a significant positive effect of
both CYP2D6 and CYP2C19 genotype scores on ODV/
VLX ratio (CYP2D6: r = 0.44,p = 0.001; CYP2C19:
r = 0.26, p = 0.009), consistent with the hypothesis that
both enzymes are involved in VLX metabolism [36]. The
highest ODV/VLX ratios were related to highest CYP2D6
activity. However, they also demonstrate that CYP2D6
and CYP2C19 allelic variants are independent predictors
of lower total concentration (CYP2D6: P = 0.021,
CYP2C19: P = 0.001).
But to date, no study has investigated the effect of
variations in both CYP2D6 CYP2C19 activity on VLX
efficacy and tolerance.
Research objectives
The goal of this project is to explore the relationship be-
tween the activity of drug-metabolizing enzymes (DME)
and transporters, assessed by a phenotypic approach,
and the concentrations of VLX + ODV, the efficacy and
tolerance of VLX.
Primary objective
To study the correlations between the concentrations of
VLX + ODV and drug metabolism variability as assessed
by a phenotypic approach.
Fig. 1 Venlafaxine metabolism
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Secondary objectives
i. To compare between responders and non-
responders, as well as between patients with or
without side effects:
a. The CYP2C19 activity and the prevalence of each
profile of metabolism.
b. The CYP2D6 activity and the prevalence of each
profile of metabolism.
c. The CYP3A4 activity and the prevalence of each
profile of metabolism.
d. The P-gp activity and the prevalence of each pro-
file of transport.
ii. To study the correlation between VLX + ODV
concentration/dose and VLX + ODV concentration
and antidepressant efficacy and tolerance.
iii. To study the correlation between the ratio ODV/
VLX and CYP2D6 activity.
iv. To study the correlation between the concentration
at 2 h and the AUC (2,3,6 h) of the metabolic ratio
hydroxyomeprazole/omeprazole.
v. To conduct exploratory association analyses between
blood biomarkers (candidate mRNA and miRNA)
and the tolerance and efficacy of VLX.
vi. To analyse the role of genetic variations of DNA in
the determination of CYP2C19 and 2D6 phenotypes,
in patients with PM profile.
Methods
This study is a multicentre prospective non-randomized
open trial.
Patients
In this study, male and female patients, aged from 18 to
80 years, with a major depressive episode meeting DSM-
V criteria, will be eligible for participation.
Inclusion criteria include: 1) MADRS over or equal to
20 at selection visit, 2) treatment with VLX regardless of
the dose during at least 4 weeks, 3) Decision of the treat-
ing psychiatrist to increase the dose of VLX at the selec-
tion visit, 5) Understanding of the French language and
able to give written informed consent, 6) Informed con-
sent to participation in the study signed, 7) Individuals
covered by social security regimen.
Exclusion criteria include: 1) Patients treated by more
than one antidepressant other than mirtazapine or mian-
serine, 2) Patients currently treated with one of the con-
stituents of the substrate cocktail and/or by esomeprazole,
3) Sensitivity or contra-indications to any of the substrate
drugs used, 4) Current pregnancy or intention to become
pregnant, or breastfeeding, 5) Diagnosis of Bipolar dis-
order or schizophrenia.
Recruitment and design
All 11 recruitment sites are coordinated by the Fonda-
Mental foundation (www.fondation.fondamental.org)
and belong to the Network of expert centres for Resist-
ant Depression. Comprehensive assessment is offered
to patients with resistant depression and data are
entered into dedicated web-based application (e-DR).
Patients are referred to the expert centre by a general
practitioner or a psychiatrist. Psychiatrists recruit pa-
tients in hospital or ambulatory setting. Two rating
scales for depression are performed during the selection
visit; the Montgomery and Asberg Depression Rating
Scale (MADRS) and the Hamilton Rating Scale for
Depression (HAM-D). Dependent upon psychiatric
evaluation and in accordance with usual practice, the
psychiatrist (and investigator) propose an increase in
dosage if this is indicated. In this context, the investiga-
tor gives oral and written information about the study.
Subsequent visits are planned as per Fig. 2.
Inclusion visit (V0)
The visit takes place 0–20 days after the increase in
VLX dosage (selection visit). The investigator obtains
the written informed consent and several questionnaires
are completed (Table 1).
The phenotype visit (V1)
The visit will take place between 7 and 21 days after
Visit V0, in the morning.
The minimal delay between Visit V0 and Visit V1 will
include the time to reach steady state of antidepressant
drug since the increase in VLX dosage. Several criteria
will be verified:
 Compliance with the prescribed medication regimen
will be verified from the medication diary: an
oversight of a single dose of VLX during the four
days before V1 will exclude the patient.
 Minimum delay of 7 days between Visit V0 and
Visit V1.
 No change in VLX dosage or co-medications (anti-
psychotics only) between inclusion and Visit V1.
 Negative urinary pregnancy test. The test will be
performed for women of childbearing age in the
morning before cocktail administration.
 No intake of usual drugs in the morning of the
cocktail administration. Fasting state since almost
12 h. Last VLX intake 20–30 h before.
If the patient does not meet these criteria, they will be
excluded from the study.
The nurse will then collect 4 venous blood samples be-
fore the administration of the substrate cocktail.
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 Two samples of 5 ml for the concentration of VLX
and ODV (heparinised capillary tubes)
 One sample of 7 mL for DNA collection (EDTA tube)
 One sample of 2.5 mL in PAXgen according to
standardized procedure
In the morning after an overnight fast, the following
cocktail of probe drugs are administered to the patients
by a nurse: omeprazole 10 mg (capsule), dextromethor-
phane bromhydrate 10 mg (oral liquid formulation),
midazolam 1 mg (injectable solution for oral administra-
tion), fexofenadine 120 mg (tablet). The pill and liquid
formulations will be taken orally successively with a glass
of water.
The blood samples will be collected as follow: Capil-
lary blood samples at 2, 3 and 6 h after the cocktail ad-
ministration (1 drops each hour) from a small finger
prick will be collected using the Dried Blood Spot sam-
pling method (Fig. 2), for the measurement of cocktail
drug concentrations (drug parent and metabolites). To
simplify the process of capillary blood collection, a
device called HemaXis™ has been developed by DBS Sys-
tem SA (Switzerland) [37]. The HemaXis device inte-
grates a patented microfluidic plate (WO/2013/144743)
allowing accurate volume control and a conventional
filter paper card for blood storage. Using this novel de-
vice, 10 μL-DBS samples can be easily generated from
capillary blood drop without additional manipulation.
Preliminary results show excellent performances in
terms of precision of collected volume and ease of use.
In addition, alimentation during the preceding 7 days
will be recorded by a standardized brief questionnaire.
Patients will be questioned and monitored at each blood
sampling: Diziness (yes/no); Headache (yes/no); Nausea,
vomiting (yes/no), cardiac frequency (yes/no), systolic
and diastolic tension. Breakfast will be possible 1 h after
taking the cocktail drugs.
Follow-up visits (V2 and V3)
The visits V2 and V3 will take place between 25 and
40 days (4 weeks) and 50–70 days (8 weeks) after Visit V0,
with a psychologist or a practitioner. They include assess-
ment of efficacy, tolerance and observance. Once the V3
achieved, the study is finished for the patient who con-
tinues its usual follow-up.
Recruitment is expected to be completed within ap-
proximately 2 years.
Assessment criteria
Primary assessment criteria
CYP2C19 activity: 5-hydroxyomeprazole/omeprazole at
2 h and AUC2,3,6 of the Metabolic ratio 2, 3 and 6 h after
omeprazole oral administration.
CYP2D6 activity: dextrorphan/dextromethorphan ratio
two hours after dextromethorphan oral administration.
Fig. 2 Summary of MARVEL design. V (Venlafaxine), ODV (O-demethyl-Venlafaxine). MADRS (Montgomery and Asberg Depression Rating Scale);
HAM-D (Hamilton Rating Scale for Depression). V0 (Inclusion Visit), V1 (Phenotypic visit)
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CYP3A4 activity: 1-hydroxymidazolam/ midazolam ra-
tio two hours after midazolam oral administration.
P-gp activity: Fexofenadine AUC2,3,6 based on fexofe-
nadine concentrations at 2, 3 and 6 h after fexofenadine
oral administration.
Antidepressant concentrations: VLX + ODV.
Secondary assessment criteria
The MADRS is a ten-item diagnostic questionnaire, which
psychiatrists use to measure the severity of depressive epi-
sodes in patients with mood disorders [38, 39]. It was de-
signed in 1979 by British and Swedish researchers as an
adjunct to the HAMD, which would be more sensitive to
the changes brought on by antidepressants and other
forms of treatment than the Hamilton Scale alone was.
There is, however, a high degree of statistical correlation
between scores on the two measures. Each item is coded 0
to 6 by the physician, the maximal score is 60; Depression
is defined by a score ≥ 15. MADRS remission is defined
by a score less than 10 and.
Patient responders to VLX are defined by a 50% de-
crease in MADRS score at 8 weeks of VLX treatment in
comparison with MADRS score measured during patient
selection.
The HAMD is a multiple item questionnaire used to
provide an indication of depression, and as a guide to
evaluate recovery (hedlund, hamiltton). The question-
naire is designed for adults and is used to rate the
severity of their depression by probing mood, feelings
of guilt, suicidal ideation, insomnia, agitation or retard-
ation, anxiety, weight loss, and somatic symptoms.
Initially considered the “Gold Standard” for rating de-
pression in clinical research, this scale should not be
used as a diagnostic instrument.
The original 1960 version contains 17 items to be rated
(HRSD-17), but three other questions are not added to
the total score and are used to provide additional clinical
information. Although Hamilton’s original scale had 17
items, other versions were developed to include up to 29
items (HRSD-29). Each item on the questionnaire is
scored on a 3 or 5-point scale, depending on the item, and
the total score is compared to the corresponding descrip-
tor. Remission of a MDD is defined as a HAM-D score of
less than 10 (Williams 88).
The Medication Adherence Report Scale (MARS): The
MARS scale is a ten-item self-report measure of medica-
tion adherence, initially developed for schizophrenia [40].
Brief scale for anxiety: The brief scale for anxiety of
Tyrer is a subdivision of the comprehensive psychopatho-
logical scale [41]. It is a clinical interview rating scale de-
signed to assess the psychology and somatic symptoms of
anxiety; the interviewer rates the subject on each of 10
symptoms on a 7-point scale from 0 (no occurrence of the
symptom) to 7 (incapacitation by lack of control of the
symptom).
Criteria for rating medication trials for antidepressant
failure: The Antidepressant Treatment History Form
(ATHF) consists of scoring instructions and ratings for
most antidepressants, augmentation and Electro convul-
sive therapy trials. It is being used increasingly to deter-
mine the adequacy of antidepressant trials.
Others: Most complaints listed as adverse reactions
in people with depression are more common when they
were medication-free rather than during their treat-
ment with antidepressants [42]. The Frequency, Inten-
sity, and Burden of Side Effects Rating (FIBSER) Scale,
was developed to document these three domains of side
effects in patients treated in the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) project.
The FIBSER is a reliable and valid self-report measure
of side effects in a population receiving treatment for
depression. Although it does not measure the impact of
specific side effects, it does measure three domains of
impact: frequency, intensity, and burden of the side ef-
fects. Its brevity makes it a useful tool for routine clin-
ical practice.
Side effects are evaluated with the Patient Rated In-
ventory of Side Effects (PRISE-M) [43]. It is a 31-item
checklist of side effects rated for the last 7 days, classi-
fied by symptom domains i.e. gastrointestinal, cardiac,
skin, nervous system, eyes/ears, genital/urinary, sleep,
sexual functioning, and other. Each domain has multiple
symptoms that can be endorsed. For each domain the
patient rates whether or not the symptoms are absent
(0) tolerable [1] or distressing [2]. A total score defines a
global side effects level, which takes into account the fre-
quency and severity of each side effect. The frequency
(% patients with the side effect tolerable or distressing)
and severity of each side effect or of each domain can
also be calculated. Patients with side effects are defined
by a PRISE-M score > 10.
Fagerström Test measures nicotine dependence.
Phenotypic analysis
From DBS to determination of phenotype
DBS devices will be frozen at −20 °C pending transport
and analysis. The enzymatic activities will be assessed by
specific metabolite/probe concentration ratios (meta-
bolic ratios-MR) from a sample taken 2 h after cocktail
administration for CYP2C19, CYP3A4, CYP2D6; and by
the determination of the limited area under the curve
(AUC) from the sample taken 2–3 and 6 h after cocktail
administration for CYP2C19 and P-gp.
The cocktail substrates and their CYP-specific metabo-
lites will be quantified in DBS using a single reverse-
phase high-performance liquid chromatography–tandem
mass spectrometry method operating in dual electrospray
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ionization mode, as previously described [44, 45]. The
substances of interest will be extracted from DBS samples
using methanol, whereas protein precipitation using
acetonitrile will be used for plasma extraction. This
method has been fully validated according to international
criteria. The phenotype will be determined according to
the results of the MR, and based on the results of previous
studies [45].
Drug concentration
Blood samples will be centrifuged and serum will be col-
lected in glass tubes. They will be frozen at −20 °C until
transport and analysis. Plasma concentration will be
quantified using Liquid chromatography coupled to UV
visible diode array detector.
DNA collection and circulating mRNA
For DNA analysis, blood samples will be conserved in a
7 mL EDTA tube. For RNA analysis, blood samples will
be conserved in PAXGEN tubes at ambient temperature
for 2-72 h in a vertical position; they will then be frozen
at −20 °C. Specific Genetic analyses will be decided upon
at the end of the study.
Statistics
Statistical analysis will be performed when the sample
size has been reached, and all the end point measures
available.
Remission rates with citalopram as the first step in
STAR*D study were 28 to 33%, and response rates aver-
aged 47% [46] after 14 weeks of treatment. After unsuc-
cessful treatment with an SSRI, 28% of patients had a
remission of symptoms after switching to VLX after
14 weeks of treatment. Schweitzer et al. observed, in pa-
tients suffering with moderate depression (MADRS = 32.8
at entry) that 69% were responders to VLX after 8 weeks
of treatment and 36.7% were in remission. Hence, the
proportion of remitters and responders vary according
to the study; the prevalence of responders is higher than
remitters and the time to assess these criteria also vary
according to these studies. Schweitzeir et al. showed that
in patients who were responders to VLX at 8 weeks, the
response was maintained and even improved up to
10 months after [47]. Moreover, it is recognized that the
antidepressant should be administered for 4 to 6 weeks
before non-response can be assumed [48].
Given these data we estimate that response rates to
VLX at 8 weeks will be 40%. We hypothesize that the
prevalence of patients with a CYP2C19 UM profile is
twice as high in non-responders in comparison with re-
sponders, who have a CYP2C19 metabolic profile com-
parable to that of Caucasians (20%). To demonstrate
that the prevalence is two-fold that observed in non-
responders, with a type I error at 0.05 and a statistical
power of 80%, the sample size is tabulated below accord-
ing to the prevalence of response (Table 2).
In anticipation of potential large disproportions be-
tween responders and non-responders (which will only
be defined after study inclusion) we decided to include
205 patients. This will allow controlling for type I and
typing II error rates in the comparison of the prevalence
of CYP2C19 UMs among these groups.
In addition the sample size will allow to study suffi-
cient numbers of CYP2D6 PMs, IMs, and UMs to deter-
mine the effects of CYP2D6 variations on VLX and
ODV plasma levels and their efficacy or risk of adverse
events.
The type I error rate will be fixed at 0.05. All tests will
be two-sided and compared thus to 0.05.
Multiple imputation, which is a popular approach for
handling the pervasive problem of missing data in bio-
statistics, will be used [49]. It is usually performed under
a missing at random assumption [50]. Multiple imputa-
tions by chained equation are to our knowledge the
most flexible approach to handle complex patterns of
missing data (including categorical data, quantitative
data, and survival data).
Primary analyses will be performed on an intent-to-treat
basis. Secondary exploratory analyses will consider the
population of compliers, that is, those who completed the
treatment according to the scheduled protocol.
Ethics
Ethical approval was obtained by an Independent Ethics
Committee (CPP Ile de France I, Paris) and by the
Agence Française de Sécurité Sanitaire des Produits de
Santé (ANSM, French Health Products Safety Agency).
The study was registered at the ClinicalTrials.gov web-
site (NCT02590185).
Discussion
In everyday practice, it remains difficult to accurately pre-
dict which patients will respond to which antidepressant
and at which dose. Most of the research on the effect of
metabolism and transport variability on antidepressants
PK and PD was conducted either in healthy subjects or in
patients using a genetic approach [8]; these studies often
confirmed a relationship for a given drug/DME inter-
action but they did not investigate the cumulative effect of
multiple metabolic pathways. Several studies concentrated
Table 2 Computation of sample size
Expected prevalence
of responders
Number of
responders
Number of
non responders
Total sample
size
50% 82 82 164
33% 63 125 188
28% 59 146 205
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on exploring the PK variability of tricyclic antidepressant,
which currently are prescribed less frequently relative to
other antidepressant classes.
The implementation of an assay able to predict the
dose most likely to achieve maximal therapeutic benefit
with minimal/tolerable adverse effects for a given patient
may reduce the socioeconomic burden associated with
suboptimal treatment. The Geneva Cocktail Phenotypic
approach presents several advantages including the “in
vivo” measure of different cytochromes and transporter
P-gp activities, their simultaneous determination in a
single test, avoiding the influence of variability over time
on phenotyping results, the administration of low dose
substrates, a limited sampling strategy with an analytical
method developed on DBS analysis. By showing an asso-
ciation between drug metabolism and VLX concentra-
tions, efficacy and tolerance, there is a hope that testing
drug metabolism pathways with a phenotypical approach
would help physicians in selecting and dosing
antidepressants.
We recognize that therapeutic drug monitoring (TDM)
may also help to find the right dosage for an individual pa-
tient, especially during start of therapy. But prior to and in
addition to TDM, information about the activity of several
metabolic pathways could further improve this dose find-
ing and the choice of a given antidepressant.
A possible limitation of this study is that phenotyping is
performed after the antidepressant has already been
started for several days; antidepressants themselves are
known to modify drug metabolism (ref), It would be ideal
to evaluate the information before treatment has started.
However this does not reflect clinical reality. Most pa-
tients still receive an antidepressant, with its respective in-
fluence on drug metabolism, when the psychiatrist takes
the decision to switch. Waiting for the complete extinc-
tion of an inhibitory effect before performing a phenotypic
determination of drug metabolism and before starting
pharmacotherapy could delay pharmacotherapy and is,
therefore, unwanted. Obviously a genotypic approach to
defining drug metabolism is a very interesting method for
exploring drug metabolism variability but has its own
limits as detailed in the introduction. TDM of antidepres-
sant, phenotyping and genotyping are complementary,
and their combined use could contribute to improve the
understanding of the determinants of the response to
antidepressants.
Finally, the MARVEL study will provide an important
contribution to increasing the knowledge of VLX vari-
ability and in optimizing the use of methods of personal-
ized therapy in psychiatric settings.
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